Novo Nordisk to end German sales of new insulin drug after price row

03 Jul 2015


Novo Nordisk, the world's biggest insulin producer, is to stop selling its new long-acting insulin drug Tresiba in Germany following a row over pricing.

Reuters


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story